AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9135227 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline infusions
Number of subjects: 20
Study 9135227 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (7.5 mg/day for three days, open label)
Number of subjects: 20
Study 7955026 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ-HT, 5 months)
Number of subjects: 0
Study 7955026 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz (SW-HT, 5 months)
Number of subjects: 0
Study 7955026 — intervention group
Group type: COMPARATOR
Intervention: Schwarz (SW-std, 10 months)
Number of subjects: 0
Study 7955026 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ-HT, 5 months) for females
Number of subjects: 0
Study 7955026 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz (SW-HT, 5 months) for females
Number of subjects: 0
Study 7955026 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titre measles vaccine (EZ-HT, SW-HT)
Number of subjects: 0
Study 3680601 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (64 mg) + Aspirin (800 mg)
Number of subjects: 0
Study 3680601 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (64 mg)
Number of subjects: 0
Study 3680601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3680601 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (800 mg)
Number of subjects: 0
Study 28064163 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 12.5-50 mg/day
Number of subjects: 111
Study 28064163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 27917793 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. furosemide (200‐300 mg bid) and 3% hypotonic saline solution (HSS) (once or twice a day)
Number of subjects: 78
Study 27917793 — intervention group
Group type: EXPERIMENTAL
Intervention: oral furosemide tablets (360‐520 mg bid) and salt (2.5 g bid)
Number of subjects: 78
Study 27917793 — intervention group
Group type: COMPARATOR
Intervention: repeated large‐volume‐paracentesis (RLVP) with albumin infusion
Number of subjects: 78
Study 24873894 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean leaf extracts (SLE) 2 g per day
Number of subjects: 0
Study 24873894 — intervention group
Group type: EXPERIMENTAL
Intervention: Banaba extracts (BE) 300 mg per day
Number of subjects: 0
Study 24873894 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch 2 g per day)
Number of subjects: 0
Study 22854988 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet‐leukocyte membrane
Number of subjects: 80
Study 22854988 — intervention group
Group type: COMPARATOR
Intervention: No platelet‐leukocyte membrane
Number of subjects: 80
Study 19958442 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD plus bone grafts
Number of subjects: 28
Study 19958442 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD plus membranes
Number of subjects: 28
Study 19958442 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD with bovine bone grafts
Number of subjects: 28
Study 19958442 — intervention group
Group type: COMPARATOR
Intervention: EMD alone
Number of subjects: 28
Study 18356794 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual GP care
Number of subjects: 30
Study 18356794 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care alone
Number of subjects: 30
Study 15756156 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: midazolam (0.015‐0.030 mg/kg) and sufentanil (0.15‐0.20 microg/kg)
Number of subjects: 65
Study 15756156 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: midazolam (0.15‐0.2 mg/kg) and continuous remifentanil infusion 0.5‐1 microg/kg/min followed by 0.05 microg/kg/min
Number of subjects: 65
Study 12479634 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous connective tissue graft (CT group)
Number of subjects: 30
Study 12479634 — intervention group
Group type: COMPARATOR
Intervention: Acellular dermal matrix (ADM group)
Number of subjects: 30
Study 10515145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC (unetched enamel, wet condition)
Number of subjects: 30
Study 10515145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC (unetched enamel, dry condition)
Number of subjects: 30
Study 10515145 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience L3 (etched enamel)
Number of subjects: 30
Study 10515145 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Bond (etched enamel)
Number of subjects: 30
Study 10515145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC (in vivo)
Number of subjects: 30
Study 10515145 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resins (in vivo)
Number of subjects: 30
Study 7670590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal injection of prostaglandin E1 with RMRI penile clamp
Number of subjects: 0
Study 7670590 — intervention group
Group type: COMPARATOR
Intervention: Intracavernosal injection of prostaglandin E1 without RMRI penile clamp
Number of subjects: 0
Study 2348457 — intervention group
Group type: EXPERIMENTAL
Intervention: High-demand preface
Number of subjects: 126
Study 2348457 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-demand preface
Number of subjects: 126
Study 2348457 — intervention group
Group type: COMPARATOR
Intervention: No-preface (control)
Number of subjects: 126
Study 1267438 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered cephalothin
Number of subjects: 12
Study 1267438 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered cephalothin
Number of subjects: 12
Study 1267438 — intervention group
Group type: COMPARATOR
Intervention: Diluent alone (5% dextrose in water)
Number of subjects: 12
Study 31816191 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of 1:100,000 epinephrine injected intranasally
Number of subjects: 28
Study 31816191 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of 1:200,000 epinephrine injected intranasally
Number of subjects: 28
Study 31816191 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1:1000 epinephrine pledgets placed after injection of epinephrine
Number of subjects: 28
Study 31037544 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragility Index calculation
Number of subjects: 39
Study 31037544 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of Bias evaluation using Cochrane Tool 2.0
Number of subjects: 39
Study 28646975 — intervention group
Group type: EXPERIMENTAL
Intervention: IY TCM training
Number of subjects: 42
Study 28646975 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 42
Study 26071656 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 99
Study 26071656 — intervention group
Group type: COMPARATOR
Intervention: Sham-CPAP
Number of subjects: 99
Study 26071656 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct LDL-C
Number of subjects: 99
Study 26071656 — intervention group
Group type: EXPERIMENTAL
Intervention: oxLDL
Number of subjects: 99
Study 23150678 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at 4, 8, and 40 mU/m2 · min during a three-stage hyperinsulinemic/euglycemic clamp after dietary control and overnight insulin infusion.
Number of subjects: 50
Study 21770925 — intervention group
Group type: EXPERIMENTAL
Intervention: USL255 (200 mg) in fasted conditions
Number of subjects: 36
Study 21770925 — intervention group
Group type: EXPERIMENTAL
Intervention: USL255 (200 mg) in fed conditions
Number of subjects: 36
Study 21770925 — intervention group
Group type: COMPARATOR
Intervention: Topamax (100 mg) administered 12 h apart
Number of subjects: 36
Study 19325515 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (75 mg/kg/d for 1 day) with albendazole (15 mg/kg/d for 7 days)
Number of subjects: 112
Study 19325515 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (15 mg/kg/d for 7 days)
Number of subjects: 112
Study 17661565 — intervention group
Group type: EXPERIMENTAL
Intervention: 6000 IU vitamin D3 plus 400 IU prenatal vitamin
Number of subjects: 19
Study 17661565 — intervention group
Group type: COMPARATOR
Intervention: 400 IU vitamin D3/day (control)
Number of subjects: 19
Study 17661565 — intervention group
Group type: EXPERIMENTAL
Intervention: 6400 IU vitamin D3/day
Number of subjects: 19
Study 17661565 — intervention group
Group type: COMPARATOR
Intervention: Oral vitamin D supplementation (control for infants)
Number of subjects: 19
Study 14974311 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 litres PEG 4000
Number of subjects: 140
Study 14974311 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 litres PEG 3350
Number of subjects: 140
Study 14974311 — intervention group
Group type: COMPARATOR
Intervention: 90 ml sodium phosphate with an additional 2.5 litres of fluid
Number of subjects: 140
Study 14974311 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PEG solutions (PEG 4000 and PEG 3350)
Number of subjects: 140
Study 11350539 — intervention group
Group type: EXPERIMENTAL
Intervention: Recocef (Julphar, UAE)
Number of subjects: 25
Study 11350539 — intervention group
Group type: COMPARATOR
Intervention: Ceclor (Eli Lilly, UK)
Number of subjects: 25
Study 10771930 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular transfusion therapy
Number of subjects: 71
Study 10771930 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypoxia and iron overload
Number of subjects: 71
Study 7948455 — intervention group
Group type: EXPERIMENTAL
Intervention: White 1.5‐hr dawn simulation peaking at 250 lux
Number of subjects: 19
Study 7948455 — intervention group
Group type: COMPARATOR
Intervention: Red 1.5‐hr dawn signal peaking at 2 lux
Number of subjects: 19
Study 3286684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 3286684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30630184 — intervention group
Group type: EXPERIMENTAL
Intervention: Round window niche drilling combined with daily intratympanic methylprednisolone for 7 times
Number of subjects: 20
Study 30630184 — intervention group
Group type: COMPARATOR
Intervention: Daily intratympanic methylprednisolone for 7 times
Number of subjects: 20
Study 28526033 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 26
Study 28526033 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 26
Study 26114347 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 74
Study 26114347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 23953030 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 3-weekly 350 mg/m² (or 300 mg/m² if age >70 or performance status (PS)=2)
Number of subjects: 672
Study 23953030 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan 3-weekly 140 mg/m² (120 mg/m² if age >70 or PS=2) with ciclosporin 3 mg/kg t.d.s. for three days by mouth starting on the morning before irinotecan
Number of subjects: 672
Study 23953030 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan
Number of subjects: 672
Study 23953030 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan plus ciclosporin
Number of subjects: 672
Study 21050027 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal budesonide 100 μg, 1 puff per nostril twice a day
Number of subjects: 20
Study 21050027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18344568 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study 18344568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16884530 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated Humidifier (HH)
Number of subjects: 104
Study 16884530 — intervention group
Group type: COMPARATOR
Intervention: Heat and Moisture Exchanger (HME)
Number of subjects: 104
Study 15640636 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled isoflurane via the Anesthetic Conserving Device
Number of subjects: 40
Study 15640636 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam infusion
Number of subjects: 40
Study 11699174 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching agent (Opalescence/Ultradent)
Number of subjects: 30
Study 11699174 — intervention group
Group type: COMPARATOR
Intervention: Placebo agent (PLA)
Number of subjects: 30
Study 9159691 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical heparin eyedrops
Number of subjects: 200
Study 9159691 — intervention group
Group type: COMPARATOR
Intervention: Control group (no eyedrops)
Number of subjects: 200
Study 7960021 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline hypertension group
Number of subjects: 150
Study 3371309 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtelephonic coronary intervention system
Number of subjects: 238
Study 3371309 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (control)
Number of subjects: 238
Study 30730938 — intervention group
Group type: EXPERIMENTAL
Intervention: Single power posing session
Number of subjects: 41
Study 30730938 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily power posing practice
Number of subjects: 41
Study 30730938 — intervention group
Group type: COMPARATOR
Intervention: No practice (control)
Number of subjects: 41
Study 28676071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (systematic FC distress screening, privileged contact with oncology nurse, liaison with family physician)
Number of subjects: 120
Study 28676071 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 120
Study 26519345 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX 0.7
Number of subjects: 508
Study 26519345 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 508
Study 23686706 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (20,000 IU - 40,000 IU per week)
Number of subjects: 893
Study 23686706 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (1,000 mg)
Number of subjects: 893
Study 23686706 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both vitamin D and testosterone RCTs)
Number of subjects: 893
Study 21160218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular lidocaine 1.5 mg · kg(‐1) administered into the deltoid muscle 10 min before anaesthesia induction
Number of subjects: 75
Study 21160218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 1.5 mg · kg(‐1), 2 min before anaesthesia induction
Number of subjects: 75
Study 21160218 — intervention group
Group type: COMPARATOR
Intervention: Control group received only propofol injection
Number of subjects: 75
Study 19129263 — intervention group
Group type: EXPERIMENTAL
Intervention: Marching music
Number of subjects: 20
Study 19129263 — intervention group
Group type: EXPERIMENTAL
Intervention: Weather forecast
Number of subjects: 20
Study 19129263 — intervention group
Group type: COMPARATOR
Intervention: Ignoring auditory stimulus
Number of subjects: 20
Study 19129263 — intervention group
Group type: COMPARATOR
Intervention: No auditory stimulus
Number of subjects: 20
Study 17371412 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centered therapy
Number of subjects: 33
Study 17371412 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 33
Study 15726852 — intervention group
Group type: EXPERIMENTAL
Intervention: CTiP-fabricated frameworks directly to Brånemark implants
Number of subjects: 36
Study 15726852 — intervention group
Group type: COMPARATOR
Intervention: Brånemark implant/abutment assemblies
Number of subjects: 36
Study 11768928 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination against varicella
Number of subjects: 0
Study 11768928 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir, valacyclovir, famciclovir
Number of subjects: 0
Study 11768928 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics, tricyclic antidepressants, and other agents
Number of subjects: 0
Study 9492664 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (200,000 IU) plus 25 IU vitamin E
Number of subjects: 83
Study 9492664 — intervention group
Group type: COMPARATOR
Intervention: Control (25 IU vitamin E)
Number of subjects: 83
Study 8116784 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with a flashlight attached to the hook of the prosthesis to connect dots on paper
Number of subjects: 52
Study 8116784 — intervention group
Group type: COMPARATOR
Intervention: Practice moving an equally weighted prosthesis without the light or dots
Number of subjects: 52
Study 3046824 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline 5 ng min‐1 kg‐1 infused over 30 min
Number of subjects: 6
Study 3046824 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline 15 ng min‐1 kg‐1 infused over 30 min
Number of subjects: 6
Study 29621810 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT in plain (GE)
Number of subjects: 17
Study 29621810 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT in uphill (GB)
Number of subjects: 17
Study 26705299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative cell salvage (CS)
Number of subjects: 195
Study 26705299 — intervention group
Group type: COMPARATOR
Intervention: Control (no cell salvage)
Number of subjects: 195
Study 25636071 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 33,000 IU
Number of subjects: 40
Study 25636071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25636071 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 40
Study 23690420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus radiation therapy (TamRT)
Number of subjects: 636
Study 23690420 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone (Tam)
Number of subjects: 636
Study 23690420 — intervention group
Group type: EXPERIMENTAL
Intervention: TamRT
Number of subjects: 636
Study 23690420 — intervention group
Group type: COMPARATOR
Intervention: Tam
Number of subjects: 636
Study 20953559 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical quercetin applied two to three dabs three times daily
Number of subjects: 40
Study 20953559 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine hydrochloride mouthwash used three times daily
Number of subjects: 40
Study 18957134 — intervention group
Group type: EXPERIMENTAL
Intervention: high-phospholipid, high-PE lipid
Number of subjects: 18
Study 18957134 — intervention group
Group type: EXPERIMENTAL
Intervention: high-phospholipid, medium-PE lipid
Number of subjects: 18
Study 18957134 — intervention group
Group type: COMPARATOR
Intervention: no-phospholipid, no-PE control lipid
Number of subjects: 18
Study 18957134 — intervention group
Group type: COMPARATOR
Intervention: water control
Number of subjects: 18
Study 18957134 — intervention group
Group type: EXPERIMENTAL
Intervention: medium-PE lipid
Number of subjects: 18
Study 18957134 — intervention group
Group type: EXPERIMENTAL
Intervention: high-PE lipid
Number of subjects: 18
Study 16884341 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (twice weekly for 12 weeks)
Number of subjects: 0
Study 16884341 — intervention group
Group type: COMPARATOR
Intervention: Control group (friendly visit, twice weekly for 12 weeks)
Number of subjects: 0
Study 12828227 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin started immediately after PCI
Number of subjects: 0
Study 12828227 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 11073858 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (40% of energy from fat)
Number of subjects: 30
Study 11073858 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (5% of energy from fat)
Number of subjects: 30
Study 11073858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 30
Study 11073858 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 30
Study 8841224 — intervention group
Group type: EXPERIMENTAL
Intervention: One E2 transdermal system
Number of subjects: 324
Study 8841224 — intervention group
Group type: EXPERIMENTAL
Intervention: Two E2 transdermal systems
Number of subjects: 324
Study 8841224 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal system
Number of subjects: 324
Study 8841224 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 transdermal system
Number of subjects: 324
Study 1640953 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and chlorambucil for six months (group 1)
Number of subjects: 92
Study 1640953 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone alone for six months (group 2)
Number of subjects: 92
Study 6383908 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. group (insulin by continuous intravenous infusion)
Number of subjects: 14
Study 6383908 — intervention group
Group type: COMPARATOR
Intervention: s.c. group (conventional subcutaneous therapy)
Number of subjects: 14
Study 6383908 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. group
Number of subjects: 14
Study 6383908 — intervention group
Group type: COMPARATOR
Intervention: s.c. group
Number of subjects: 14
Study 29525768 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus an internet intervention (SupportBack)
Number of subjects: 87
Study 29525768 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus an internet intervention with additional physiotherapist telephone support
Number of subjects: 87
Study 29525768 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 87
Study 29525768 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus an internet intervention
Number of subjects: 87
Study 27210863 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization exercise (SE)
Number of subjects: 40
Study 27210863 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy (Control)
Number of subjects: 40
Study 27210863 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study 25212990 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet used throughout the surgical procedure (Group A)
Number of subjects: 60
Study 25212990 — intervention group
Group type: COMPARATOR
Intervention: Limited use of tourniquet starting from cementation to completion (Group B)
Number of subjects: 60
Study 22466349 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (200 mg twice daily for 5 weeks)
Number of subjects: 43
Study 22466349 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (100-μg patch daily for 5 weeks)
Number of subjects: 43